nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—esophageal cancer	0.774	1	CbGaD
Tafluprost—PTGS2—Cisplatin—esophageal cancer	0.131	1	CbGbCtD
Tafluprost—Iloprost—PDE4D—esophageal cancer	0.00518	1	CrCbGaD
Tafluprost—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—ALOX15—esophageal cancer	0.00517	0.0738	CbGpPWpGaD
Tafluprost—PTGFR—bronchus—esophageal cancer	0.00352	0.18	CbGeAlD
Tafluprost—PTGFR—smooth muscle tissue—esophageal cancer	0.00344	0.177	CbGeAlD
Tafluprost—PTGFR—trachea—esophageal cancer	0.00316	0.162	CbGeAlD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS1—esophageal cancer	0.00303	0.0432	CbGpPWpGaD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.00297	0.0424	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—esophageal cancer	0.00232	0.0331	CbGpPWpGaD
Tafluprost—PTGFR—lung—esophageal cancer	0.00227	0.116	CbGeAlD
Tafluprost—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—esophageal cancer	0.00201	0.0286	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—FKBP1A—esophageal cancer	0.00189	0.0269	CbGpPWpGaD
Tafluprost—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS1—esophageal cancer	0.00182	0.026	CbGpPWpGaD
Tafluprost—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—CYP2A6—esophageal cancer	0.00173	0.0246	CbGpPWpGaD
Tafluprost—PTGS2—Eicosanoid Synthesis—ALOX15—esophageal cancer	0.00171	0.0243	CbGpPWpGaD
Tafluprost—PTGFR—lymph node—esophageal cancer	0.00155	0.0796	CbGeAlD
Tafluprost—PTGS2—Overview of nanoparticle effects—PTGS1—esophageal cancer	0.00143	0.0203	CbGpPWpGaD
Tafluprost—PTGS2—Eicosanoid Synthesis—PTGS1—esophageal cancer	0.00118	0.0169	CbGpPWpGaD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—esophageal cancer	0.00116	0.0166	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC52A3—esophageal cancer	0.00106	0.0151	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—HMOX1—esophageal cancer	0.00104	0.0148	CbGpPWpGaD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—PTGS1—esophageal cancer	0.00099	0.0141	CbGpPWpGaD
Tafluprost—PTGS2—epithelium—esophageal cancer	0.000981	0.0503	CbGeAlD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—ANXA1—esophageal cancer	0.000971	0.0138	CbGpPWpGaD
Tafluprost—PTGS2—bronchus—esophageal cancer	0.000966	0.0496	CbGeAlD
Tafluprost—PTGS2—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.000949	0.0135	CbGpPWpGaD
Tafluprost—PTGS2—smooth muscle tissue—esophageal cancer	0.000946	0.0485	CbGeAlD
Tafluprost—PTGS2—Overview of nanoparticle effects—BAX—esophageal cancer	0.000945	0.0135	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CA1—esophageal cancer	0.000928	0.0132	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.000894	0.0127	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.000894	0.0127	CbGpPWpGaD
Tafluprost—PTGS2—trachea—esophageal cancer	0.000868	0.0445	CbGeAlD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—esophageal cancer	0.000863	0.0123	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—GNG7—esophageal cancer	0.00084	0.012	CbGpPWpGaD
Tafluprost—PTGS2—S1P1 pathway—KDR—esophageal cancer	0.000782	0.0111	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000756	0.0108	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG7—esophageal cancer	0.000751	0.0107	CbGpPWpGaD
Tafluprost—PTGS2—digestive system—esophageal cancer	0.000747	0.0383	CbGeAlD
Tafluprost—PTGFR—G alpha (q) signalling events—ANXA1—esophageal cancer	0.000688	0.00981	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000658	0.00938	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—GHRL—esophageal cancer	0.000652	0.0093	CbGpPWpGaD
Tafluprost—PTGS2—lung—esophageal cancer	0.000623	0.032	CbGeAlD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.000615	0.00877	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—FKBP1A—esophageal cancer	0.000615	0.00877	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.000598	0.00852	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.000583	0.00832	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO1—esophageal cancer	0.000581	0.00829	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—BCL2—esophageal cancer	0.000575	0.0082	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000559	0.00797	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00049	0.00699	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—esophageal cancer	0.000456	0.0065	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000456	0.0065	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000443	0.00632	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000432	0.00616	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000427	0.00609	CbGpPWpGaD
Tafluprost—PTGS2—lymph node—esophageal cancer	0.000426	0.0219	CbGeAlD
Tafluprost—PTGFR—GPCR ligand binding—GNG7—esophageal cancer	0.000424	0.00604	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.000418	0.00597	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000418	0.00596	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—LGALS3—esophageal cancer	0.000403	0.00574	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000388	0.00553	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL2—esophageal cancer	0.000373	0.00532	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GDI2—esophageal cancer	0.000356	0.00507	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CXCL2—esophageal cancer	0.000349	0.00498	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—ANXA1—esophageal cancer	0.000347	0.00495	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—SST—esophageal cancer	0.000338	0.00481	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—GHRL—esophageal cancer	0.000329	0.00469	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000328	0.00467	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000325	0.00463	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—ANXA1—esophageal cancer	0.000325	0.00463	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SOD2—esophageal cancer	0.000286	0.00407	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKAP13—esophageal cancer	0.000275	0.00392	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KMT2D—esophageal cancer	0.000257	0.00367	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PDE4D—esophageal cancer	0.000252	0.00359	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKAP13—esophageal cancer	0.00025	0.00356	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GNG7—esophageal cancer	0.000239	0.00341	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000236	0.00336	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ADCYAP1—esophageal cancer	0.000229	0.00327	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PDE4D—esophageal cancer	0.000229	0.00326	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000224	0.0032	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000221	0.00315	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GNG7—esophageal cancer	0.000217	0.0031	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL2—esophageal cancer	0.000211	0.00301	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—WWOX—esophageal cancer	0.00021	0.00299	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CREBBP—esophageal cancer	0.000203	0.0029	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000202	0.00288	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000201	0.00286	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—esophageal cancer	0.0002	0.00285	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FKBP1A—esophageal cancer	0.000199	0.00284	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—ANXA1—esophageal cancer	0.000196	0.0028	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000195	0.00278	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—WIF1—esophageal cancer	0.000195	0.00278	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000192	0.00274	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL2—esophageal cancer	0.000192	0.00273	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000191	0.00272	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—SST—esophageal cancer	0.000191	0.00272	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—GHRL—esophageal cancer	0.000186	0.00265	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TLR4—esophageal cancer	0.000181	0.00259	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CSNK1A1—esophageal cancer	0.00018	0.00256	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—ANXA1—esophageal cancer	0.000178	0.00254	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000178	0.00254	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—BCL2—esophageal cancer	0.000175	0.0025	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—SST—esophageal cancer	0.000173	0.00247	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—NOS2—esophageal cancer	0.000172	0.00246	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00017	0.00243	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—GHRL—esophageal cancer	0.000169	0.00241	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PFN1—esophageal cancer	0.000168	0.0024	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000165	0.00236	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000163	0.00232	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000158	0.00225	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000158	0.00225	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—RB1—esophageal cancer	0.000154	0.0022	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ELMO1—esophageal cancer	0.000151	0.00215	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CCND1—esophageal cancer	0.00015	0.00214	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000149	0.00213	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000148	0.00211	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKAP13—esophageal cancer	0.000148	0.00211	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN1A—esophageal cancer	0.000145	0.00207	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—EP300—esophageal cancer	0.000138	0.00197	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000136	0.00194	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000136	0.00193	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PDE4D—esophageal cancer	0.000135	0.00193	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GNG7—esophageal cancer	0.000128	0.00183	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC52A3—esophageal cancer	0.000126	0.00179	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MYC—esophageal cancer	0.000121	0.00172	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—XIAP—esophageal cancer	0.00012	0.00172	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KMT2D—esophageal cancer	0.00012	0.00171	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000118	0.00169	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCND1—esophageal cancer	0.000115	0.00163	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CTNNA1—esophageal cancer	0.000114	0.00162	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL2—esophageal cancer	0.000113	0.00161	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000106	0.00151	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PSME1—esophageal cancer	0.000106	0.00151	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PSME2—esophageal cancer	0.000106	0.00151	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000105	0.0015	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ANXA1—esophageal cancer	0.000105	0.0015	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—BLVRB—esophageal cancer	0.000105	0.0015	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC52A3—esophageal cancer	0.000105	0.0015	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SST—esophageal cancer	0.000102	0.00146	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH3—esophageal cancer	9.97e-05	0.00142	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GHRL—esophageal cancer	9.97e-05	0.00142	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FBXW7—esophageal cancer	9.81e-05	0.0014	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	9.4e-05	0.00134	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FKBP1A—esophageal cancer	9.29e-05	0.00132	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	9.19e-05	0.00131	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	9.08e-05	0.00129	CbGpPWpGaD
Tafluprost—PTGS2—Disease—DOCK2—esophageal cancer	9.08e-05	0.00129	CbGpPWpGaD
Tafluprost—PTGS2—Disease—WIF1—esophageal cancer	9.08e-05	0.00129	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	8.99e-05	0.00128	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH2—esophageal cancer	8.95e-05	0.00128	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC10A2—esophageal cancer	8.94e-05	0.00127	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CA1—esophageal cancer	8.94e-05	0.00127	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	8.82e-05	0.00126	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CSNK1A1—esophageal cancer	8.38e-05	0.00119	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CA2—esophageal cancer	8.18e-05	0.00117	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.99e-05	0.00114	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TGFBR2—esophageal cancer	7.94e-05	0.00113	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	7.79e-05	0.00111	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ADH7—esophageal cancer	7.6e-05	0.00108	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PLCE1—esophageal cancer	7.6e-05	0.00108	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	7.55e-05	0.00108	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	7.54e-05	0.00108	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	7.52e-05	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SMAD4—esophageal cancer	7.51e-05	0.00107	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	7.17e-05	0.00102	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ELMO1—esophageal cancer	7.04e-05	0.001	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TPI1—esophageal cancer	6.88e-05	0.000981	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GSTO1—esophageal cancer	6.88e-05	0.000981	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ADH1B—esophageal cancer	6.67e-05	0.000951	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ALDOB—esophageal cancer	6.6e-05	0.00094	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMP—esophageal cancer	6.37e-05	0.000908	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GAPDH—esophageal cancer	6.35e-05	0.000905	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIST1H2BM—esophageal cancer	6.35e-05	0.000905	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	6.25e-05	0.000891	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP26A1—esophageal cancer	6.2e-05	0.000884	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HIF1A—esophageal cancer	6.15e-05	0.000876	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	6.12e-05	0.000872	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALOX15—esophageal cancer	6.04e-05	0.000861	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KDR—esophageal cancer	5.88e-05	0.000838	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TPI1—esophageal cancer	5.76e-05	0.000822	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTO1—esophageal cancer	5.76e-05	0.000822	CbGpPWpGaD
Tafluprost—PTGS2—Disease—XIAP—esophageal cancer	5.61e-05	0.0008	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOTCH1—esophageal cancer	5.54e-05	0.000789	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALDOB—esophageal cancer	5.52e-05	0.000788	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GAPDH—esophageal cancer	5.32e-05	0.000758	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	5.31e-05	0.000757	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CRABP1—esophageal cancer	5.27e-05	0.000751	CbGpPWpGaD
Tafluprost—PTGS2—Disease—B2M—esophageal cancer	5.21e-05	0.000743	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	5.13e-05	0.000732	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CREBBP—esophageal cancer	5.02e-05	0.000716	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GNG7—esophageal cancer	5.01e-05	0.000715	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ENO1—esophageal cancer	5e-05	0.000713	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EGFR—esophageal cancer	4.93e-05	0.000703	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PSME2—esophageal cancer	4.93e-05	0.000702	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PSME1—esophageal cancer	4.93e-05	0.000702	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CALR—esophageal cancer	4.73e-05	0.000674	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CA—esophageal cancer	4.71e-05	0.000672	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ALDH2—esophageal cancer	4.7e-05	0.00067	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FBXW7—esophageal cancer	4.57e-05	0.000652	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NOS3—esophageal cancer	4.49e-05	0.000641	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTT1—esophageal cancer	4.47e-05	0.000637	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP2A6—esophageal cancer	4.42e-05	0.00063	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.4e-05	0.000627	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CA—esophageal cancer	4.28e-05	0.00061	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ERBB2—esophageal cancer	4.2e-05	0.000599	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ENO1—esophageal cancer	4.19e-05	0.000597	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTGS1—esophageal cancer	4.19e-05	0.000597	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PSME1—esophageal cancer	4.13e-05	0.000588	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PSME2—esophageal cancer	4.13e-05	0.000588	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCND1—esophageal cancer	3.71e-05	0.00053	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TGFBR2—esophageal cancer	3.7e-05	0.000527	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CDKN1A—esophageal cancer	3.59e-05	0.000512	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP1B1—esophageal cancer	3.56e-05	0.000508	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SMAD4—esophageal cancer	3.5e-05	0.000499	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EP300—esophageal cancer	3.42e-05	0.000487	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP19A1—esophageal cancer	3.35e-05	0.000477	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HMOX1—esophageal cancer	3.05e-05	0.000435	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3e-05	0.000427	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—esophageal cancer	2.98e-05	0.000425	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCB1—esophageal cancer	2.93e-05	0.000418	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGFR—esophageal cancer	2.91e-05	0.000416	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HIF1A—esophageal cancer	2.86e-05	0.000408	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOS2—esophageal cancer	2.61e-05	0.000371	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOTCH1—esophageal cancer	2.58e-05	0.000368	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CA—esophageal cancer	2.53e-05	0.000361	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TP53—esophageal cancer	2.45e-05	0.000349	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CREBBP—esophageal cancer	2.34e-05	0.000334	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.22e-05	0.000316	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NOS3—esophageal cancer	2.09e-05	0.000299	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CREBBP—esophageal cancer	1.96e-05	0.000279	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERBB2—esophageal cancer	1.96e-05	0.000279	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NOS3—esophageal cancer	1.75e-05	0.00025	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CDKN1A—esophageal cancer	1.67e-05	0.000239	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EP300—esophageal cancer	1.59e-05	0.000227	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—esophageal cancer	1.39e-05	0.000198	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGFR—esophageal cancer	1.36e-05	0.000194	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—EP300—esophageal cancer	1.33e-05	0.00019	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CA—esophageal cancer	1.18e-05	0.000168	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CA—esophageal cancer	9.87e-06	0.000141	CbGpPWpGaD
